New Modeling Supports Using Cologuard® Every Three Years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. CART
8. LLY
9. TSLA
10. FICO

Go back to New Modeling Supports Using Cologuard® Every Three Years

Exact Sciences' (EXAS) Prelim. FY15 Revenue Light of Expectations; FY16 Outlook Reaffirmed

January 11, 2016 6:22 AM EST

Exact Sciences Corp. (Nasdaq: EXAS) announced that the company completed approximately 38,000 Cologuard tests during the fourth quarter ended Dec. 31, 2015, generating approximately $14.0 million to $14.5 million in revenue. For the full year 2015, the company expects revenue to be approximately $39.0 million to $39.5 million, the result of completing approximately 104,000 Cologuard tests during its first full year of commercialization. Exact Sciences has not completed preparation of its financial statements for the quarter and full year. These revenue estimates are based on preliminary, unaudited data.

*** The Street sees FY15 revenue of $41 million.

"We saw strong demand for Cologuard and... More